McKesson/$MCK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About McKesson
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Ticker
$MCK
Sector
Primary listing
NYSE
Employees
44,000
Headquarters
Website
McKesson Metrics
BasicAdvanced
$105B
33.73
$24.95
0.51
$2.95
0.39%
Price and volume
Market cap
$105B
Beta
0.51
52-week high
$846.43
52-week low
$520.20
Average daily volume
689K
Dividend rate
$2.95
Financial strength
Current ratio
0.883
Quick ratio
0.475
Long term debt to equity
-973.233
Total debt to equity
-1,150.985
Dividend payout ratio (TTM)
11.16%
Interest coverage (TTM)
20.55%
Profitability
EBITDA (TTM)
5,401
Gross margin (TTM)
3.45%
Net profit margin (TTM)
0.84%
Operating margin (TTM)
1.30%
Effective tax rate (TTM)
22.52%
Revenue per employee (TTM)
$8,580,000
Management effectiveness
Return on assets (TTM)
4.00%
Return on equity (TTM)
-298.75%
Valuation
Price to earnings (TTM)
33.728
Price to revenue (TTM)
0.281
Price to book
-53.49
Price to tangible book (TTM)
-5.98
Price to free cash flow (TTM)
18.743
Free cash flow yield (TTM)
5.34%
Free cash flow per share (TTM)
44.906
Dividend yield (TTM)
0.35%
Forward dividend yield
0.39%
Growth
Revenue change (TTM)
20.35%
Earnings per share change (TTM)
11.87%
3-year revenue growth (CAGR)
12.04%
10-year revenue growth (CAGR)
7.51%
3-year earnings per share growth (CAGR)
39.24%
10-year earnings per share growth (CAGR)
13.56%
3-year dividend per share growth (CAGR)
14.74%
10-year dividend per share growth (CAGR)
11.46%
What the Analysts think about McKesson
Analyst ratings (Buy, Hold, Sell) for McKesson stock.
Bulls say / Bears say
McKesson’s Q1 fiscal 2026 results beat estimates with revenue of $97.83 billion and adjusted EPS of $8.26, prompting a raise in its annual profit forecast to $37.10–37.90 per share (Reuters).
The company further lifted its fiscal 2026 EPS guidance to $38.05–38.55 and raised its long-term growth targets after reorganizing into a high-margin oncology and multispecialty segment and acquiring a majority stake in Core Ventures for $2.49 billion (Reuters).
McKesson’s U.S. pharmaceutical unit delivered 25% year-over-year sales growth to $89.95 billion in Q1, driven by increased prescription volumes and specialty product distribution, reinforcing its market-leading position (Reuters).
A U.S. appeals court revived a $2.5 billion lawsuit accusing McKesson of fueling the opioid crisis by failing to report suspicious orders, exposing the company to significant legal liabilities (Reuters).
In Q2 2025 McKesson recorded a $189 million provision for bad debts tied to the bankruptcy of key customer Rite Aid, underscoring credit risk and potential earnings volatility (SEC EDGAR).
Management’s reiterated plan to spin off its Medical-Surgical Solutions unit provided no defined timeline, creating uncertainty over when strategic benefits and shareholder value will materialize (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
McKesson Financial Performance
Revenues and expenses
McKesson Earnings Performance
Company profitability
McKesson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for McKesson stock?
McKesson (MCK) has a market cap of $105B as of November 06, 2025.
What is the P/E ratio for McKesson stock?
The price to earnings (P/E) ratio for McKesson (MCK) stock is 33.73 as of November 06, 2025.
Does McKesson stock pay dividends?
Yes, the McKesson (MCK) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $2.95 and the yield is 0.39%. McKesson has a payout ratio of 11.16% on a trailing twelve-month basis.
When is the next McKesson dividend payment date?
The next McKesson (MCK) dividend payment is scheduled for January 02, 2026.
What is the beta indicator for McKesson?
McKesson (MCK) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.